Back To Education Zone


What’s on the horizon for the treatment of solid tumours in 2019?



Stay up to date with the latest developments in the treatment of solid tumours with our expert summary of what is expected at the ESMO Congress in Barcelona, Spain, 27 September–1 October 2019.

Dr Hendrik-Tobias Arkenau (Executive Medical Director of the Sarah Cannon Research Institute, London, UK), Prof. Dirk Jäger (Head of the Medical Oncology Department, University Hospital Heidelberg, Germany) and Prof. Eric Van Cutsem (Head of Clinical Digestive Oncology, KU Leuven, Belgium) review the most important challenges in treating solid tumours and how emerging data expected at the ESMO Congress 2019 could influence the future clinical management of solid tumours.

The information in this activity is intended for oncologists and other healthcare professionals involved in the treatment of patients diagnosed with solid tumours.

Learning Objectives

After watching this touchEXPERT OPINIONS, you should be able to:

  • Identify solid tumour types with the greatest unmet clinical need in terms of effective new therapy approaches
  • Discuss emerging data for new immunotherapies and targeted therapies in solid tumours and know how to identify patients that may benefit from these new treatments
  • Evaluate the rationales for different combination and sequential therapy approaches with new agents in solid tumours

Please feed back on these touchEXPERT OPINIONS on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).